Eylea

Latest articles

12d
Stamford Advocate
Drug giant Novartis is going after a $5 billion eye-drug marketat the American Academy of Opthamology annual conference, Novartis' drug broluc
Stamford Advocate / Posted 12 days ago
at the American Academy of Opthamology annual conference, Novartis' drug brolucizumab showed that it wasn't any worse than Eylea, an existing drug to treat a condition called age-related macular degeneration. Novartis' drug was also better at... Read more
2 related articles
13d
Connecticut Post
Drug giant Novartis is going after a $5 billion eye-drug marketat the American Academy of Opthamology annual conference, Novartis' drug broluc
Connecticut Post / Posted 13 days ago
at the American Academy of Opthamology annual conference, Novartis' drug brolucizumab showed that it wasn't any worse than Eylea, an existing drug to treat a condition called age-related macular degeneration. Novartis' drug was also better at... Read more
2 related articles
13d
Business Insider
Drug giant Novartis is going after a $5 billion eye-drug marketat the American Academy of Opthamology annual conference, Novartis' drug broluc
Business Insider / Posted 13 days ago
at the American Academy of Opthamology annual conference, Novartis' drug brolucizumab showed that it wasn't any worse than Eylea, an existing drug to treat a condition called age-related macular degeneration. Novartis' drug was also better at... Read more
2 related articles
13d
Channel NewsAsia
Novartis posts eye drug data amid play for Eylea's turfdata showing patients on the Swiss drugmaker's new RTH258 drug showed less dise
Channel NewsAsia / Posted 13 days ago
data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea. Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks,... Read more
15d
Channel NewsAsia
Drugmaker Regeneron's quarterly profit surges 47 percentInc reported a 47 percent jump in quarterly profit on Wednesday on higher deman
Channel NewsAsia / Posted 15 days ago
Inc reported a 47 percent jump in quarterly profit on Wednesday on higher demand for its flagship eye treatment Eylea. The U.S. biotechnology company said net income rose to US$388.3 million, or US$3.32 per share, in the third quarter... Read more
22d
North-West Evening Mail
Drug companies accused of 'holding NHS to ransom' over legal threat to Cumbria's health servicethe decision. The issue is around the licensing of the drugs. Novartis's Luce
North-West Evening Mail / Posted 22 days ago
the decision. The issue is around the licensing of the drugs. Novartis's Lucentis drug (ranibizumab) and Bayer's Eylea (aflibercept) are both licensed to treat wet AMD - a leading cause of blindness among older patients. The alternative... Read more
7 related articles
22d
The News and Star
Drug companies accused of 'holding NHS to ransom' over legal threat to Cumbria's health servicethe decision. The issue is around the licensing of the drugs. Novartis's Luce
The News and Star / Posted 22 days ago
the decision. The issue is around the licensing of the drugs. Novartis's Lucentis drug (ranibizumab) and Bayer's Eylea (aflibercept) are both licensed to treat wet AMD - a leading cause of blindness among older patients. The alternative... Read more
7 related articles
22d
Whitehaven News
Drug companies accused of 'holding NHS to ransom' over legal threat to Cumbria's health servicethe decision. The issue is around the licensing of the drugs. Novartis's Luce
Whitehaven News / Posted 22 days ago
the decision. The issue is around the licensing of the drugs. Novartis's Lucentis drug (ranibizumab) and Bayer's Eylea (aflibercept) are both licensed to treat wet AMD - a leading cause of blindness among older patients. The alternative... Read more
7 related articles
22d
West Cumberland Times & Star
Drug companies accused of 'holding NHS to ransom' over legal threat to Cumbria's health servicethe decision. The issue is around the licensing of the drugs. Novartis's Luce
West Cumberland Times & Star / Posted 22 days ago
the decision. The issue is around the licensing of the drugs. Novartis's Lucentis drug (ranibizumab) and Bayer's Eylea (aflibercept) are both licensed to treat wet AMD - a leading cause of blindness among older patients. The alternative... Read more
7 related articles
22d
chroniclelive
Held to ransom? Drug company giants' threat to North East doctorover the decision to prescribe a much cheaper drug for a serious eye condition.
chroniclelive / Posted 22 days ago
over the decision to prescribe a much cheaper drug for a serious eye condition. Lucentis (ranibizumab) and aflibercept (Eylea) are licensed to treat the condition, which is a leading cause of blindness among older patients. Avastin... Read more
7 related articles
23d
International Business Times
World's biggest drug companies could sue doctors for prescribing cheaper alternatives (AMD) – a leading cause of blindness in older patients. Currently, two drugs –
International Business Times / Posted 23 days ago
(AMD) – a leading cause of blindness in older patients. Currently, two drugs – Lucentis (ranibizumab) and aflibercept (Eylea) – manufactured by Bayer and Novartis are licensed to treat it. While Avastin is not currently licenced for wet AMD,... Read more
7 related articles
23d
Channel NewsAsia
Bayer, Novartis clash with UK doctors over use of cheap eye drugcause of sight loss. David Hambleton, head of the South Tyneside CCG, said the
Channel NewsAsia / Posted 23 days ago
cause of sight loss. David Hambleton, head of the South Tyneside CCG, said the policy of using Avastin rather than Bayer's Eylea or Novartis's Lucentis could save the regional National Health Service (NHS) 13.5 million pounds (US$18 million) a... Read more
7 related articles
23d
Daily Telegraph
Legal threat to NHS plans for cheap treatment to prevent blindnessthe “preferred” cheaper drug. The drug companies Bayer and Novartis, which mar
Daily Telegraph / Posted 23 days ago
the “preferred” cheaper drug. The drug companies Bayer and Novartis, which market the more expensive products Lucentis and Eylea, have now launched a legal challenge, the BMJ has revealed. The firms say the NHS policies breach a patient’s legal... Read more
7 related articles
29d
The Irish Times
Biopharma firm Regeneron to create 300 jobs in LimerickDublin, where it employs about 30 people. The company was established in 1988.
The Irish Times / Posted 29 days ago
Dublin, where it employs about 30 people. The company was established in 1988. Its flagship product is ophthamology drug Eylea, which treats wet age-related macular degeneration. More recently, it has brought “bad” cholesterol drug Praluent to... Read more

In this news